2024
Reactive axillary lymph nodes after COVID-19 mRNA vaccination: comparison of mRNA vs. attenuated whole-virus vaccines
Adin M, Isufi E, Wu J, Pang Y, Nguyen D, Has D, Caner C, Aboueldaha N, Mossa-Basha M, Pucar D. Reactive axillary lymph nodes after COVID-19 mRNA vaccination: comparison of mRNA vs. attenuated whole-virus vaccines. Nuclear Medicine Communications 2024, 45: 474-480. PMID: 38465449, DOI: 10.1097/mnm.0000000000001833.Peer-Reviewed Original ResearchAxillary lymph nodesWhole virus vaccineLymph nodesMRNA vaccinesNatural courseValue of clinical parametersCOVID-19 mRNA vaccinesPredictive value of clinical parametersDose of vaccine administrationPET-CT studiesCohort of oncology patientsDeauville criteriaPET criteriaClinical parametersYounger patientsSingle doseModerna recipientsJ&J vaccinePET-positiveMultivariate analysisVaccine typesOncology patientsPredictive valueVaccine administrationModerna vaccine
2022
Ipsilateral Malignant Axillary Lymphadenopathy and Contralateral Reactive Lymph Nodes in a COVID-19 Vaccine Recipient With Breast Cancer
Adin ME, Wu J, Isufi E, Tsui E, Pucar D. Ipsilateral Malignant Axillary Lymphadenopathy and Contralateral Reactive Lymph Nodes in a COVID-19 Vaccine Recipient With Breast Cancer. Journal Of Breast Cancer 2022, 25: 140-144. PMID: 35380021, PMCID: PMC9065355, DOI: 10.4048/jbc.2022.25.e12.Peer-Reviewed Case Reports and Technical NotesLymph nodesNodal enlargementAxillary lymphadenopathyMRNA coronavirus disease 2019 (COVID-19) vaccinesBilateral axillary lymph nodesCOVID-19 vaccine recipientsRight-sided lymph nodesMRNA COVID-19 vaccinationCoronavirus disease 2019 (COVID-19) vaccinesIpsilateral axillary lymphadenopathyMalignant axillary lymphadenopathyAxillary lymph nodesPre-menopausal femalesRight breast lumpBreast cancer patientsCommon benign conditionReactive lymph nodesCOVID-19 vaccinationPotential disease progressionMagnetic resonance imagingVaccine recipientsSecond doseContralateral nodesCortical thickeningBreast lump
2021
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. New England Journal Of Medicine 2021, 385: 2336-2347. PMID: 34914339, PMCID: PMC9096864, DOI: 10.1056/nejmoa2108873.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalFemaleGene Expression ProfilingHumansLymphatic MetastasisMiddle AgedNeoplasm Recurrence, LocalPostmenopausePremenopauseProspective StudiesReceptor, ErbB-2Receptors, SteroidReverse Transcriptase Polymerase Chain ReactionConceptsInvasive disease-free survivalDistant relapse-free survivalDisease-free survivalRelapse-free survivalChemotherapy benefitRecurrence scoreBreast cancerChemoendocrine therapyAdjuvant chemotherapyPostmenopausal womenPremenopausal womenLymph nodesAxillary lymph node-negative breast cancerLymph node-negative breast cancerPositive axillary lymph nodesHER2-negative breast cancerNode-positive breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Positive lymph node diseasePositive lymph nodesSecondary end pointsAxillary lymph nodesLymph node diseaseGrowth factor receptor 2
2020
Epithelium Involving Bilateral Axillary Lymph Nodes: Metastasis, Misplaced, or Mullerian!
Singh K, Sardana R, Quddus MR, Harigopal M. Epithelium Involving Bilateral Axillary Lymph Nodes: Metastasis, Misplaced, or Mullerian! International Journal Of Surgical Pathology 2020, 29: 284-288. PMID: 32924678, DOI: 10.1177/1066896920958121.Peer-Reviewed Original ResearchConceptsSentinel lymph nodesBilateral axillary lymph nodesAxillary sentinel lymph nodesAxillary lymph nodesFrozen section examinationLymph nodesDifferential diagnosisEpithelial depositsSection examinationBreast cancer stagingNodal depositsCancer stagingHistological evaluationEpithelial restsEndosalpingiosisFirst caseDiagnosisEpitheliumExaminationMetastasisStagingMullerian
2019
Clinical-grade computational pathology using weakly supervised deep learning on whole slide images
Campanella G, Hanna M, Geneslaw L, Miraflor A, Werneck Krauss Silva V, Busam K, Brogi E, Reuter V, Klimstra D, Fuchs T. Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. Nature Medicine 2019, 25: 1301-1309. PMID: 31308507, PMCID: PMC7418463, DOI: 10.1038/s41591-019-0508-1.Peer-Reviewed Original ResearchConceptsDecision support systemWhole slide imagesTrain accurate classification modelsManually annotated datasetDevelopment of decision support systemsSlide imagesPixel-wise manual annotationSupervised deep learningSupport systemAccurate classification modelDeep learning systemComputer decision support systemDeep learningManual annotationData curationClassification modelLearning systemComputational pathologyDatasetDeploymentMetastasis to axillary lymph nodesAxillary lymph nodesBasal cell carcinomaClinical practiceImages
2015
Postmastectomy Radiation Therapy for Women With 1-3 Positive Axillary Lymph Nodes: Patterns of Care Analysis
Park H, Rutter C, An Y, Killelea B, Evans S. Postmastectomy Radiation Therapy for Women With 1-3 Positive Axillary Lymph Nodes: Patterns of Care Analysis. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e5. DOI: 10.1016/j.ijrobp.2015.07.557.Peer-Reviewed Original ResearchNeoadjuvant Dual HER2‐Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2‐Positive Breast Cancer: A Meta‐Analysis of Randomized Prospective Clinical Trials
Hicks M, Macrae E, Abdel‐Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R. Neoadjuvant Dual HER2‐Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2‐Positive Breast Cancer: A Meta‐Analysis of Randomized Prospective Clinical Trials. The Oncologist 2015, 20: 337-343. PMID: 25732265, PMCID: PMC4391765, DOI: 10.1634/theoncologist.2014-0334.Peer-Reviewed Original ResearchConceptsAddition of lapatinibHER2-positive breast cancerNeoadjuvant chemotherapyBreast cancerLymph nodesClinical trialsEarly-stage HER2-positive breast cancerSan Antonio Breast Cancer SymposiumPathologic complete response rateEarly-stage breast cancerResidual invasive cancerResidual invasive carcinomaComplete response rateOperable breast cancerAxillary lymph nodesPathologic complete responseProspective clinical trialsStage breast cancerRates of pCRDual HER2NAC armProspective RCTsCancer SymposiumPCR rateComplete response
2013
Evaluation of Novel Orthotopic Nude Mouse Models for Human Small-Cell Lung Cancer
Isobe T, Onn A, Morgensztern D, Jacoby JJ, Wu W, Shintani T, Itasaka S, Shibuya K, Koo PJ, O'Reilly MS, Herbst RS. Evaluation of Novel Orthotopic Nude Mouse Models for Human Small-Cell Lung Cancer. Journal Of Thoracic Oncology 2013, 8: 140-146. PMID: 23328546, DOI: 10.1097/jto.0b013e3182725ff9.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerHuman small cell lung cancerLymph nodesLung cancerMurine modelOrthotopic nude mouse modelHuman SCLC tumorsAxillary lymph nodesOrthotopic murine modelNovel therapeutic strategiesSubcutaneous xenograft modelTumor growth patternNude mouse modelEffective murine modelLeft lungRight lungTumor sizeSolitary massSCLC tumorsOrthotopic modelMouse modelNew therapiesTherapeutic strategiesXenograft modelNude miceManagement of the axilla II
Dominici L, Golshan M. Management of the axilla II. 2013, 441-446. DOI: 10.1201/b13937-44.Peer-Reviewed Original ResearchSystemic therapyBreast cancerTumor biologyIndividual patient's tumor biologyAdjuvant treatment recommendationsPatient's tumor biologyAxillary lymph nodesWhole breast irradiationPatients breast cancerNovel chemotherapeutic agentsEndocrine therapyLocal therapyLymph nodesTreatment recommendationsAromatase inhibitorsRadiation therapyLocal controlTherapyChemotherapeutic agentsAccelerated formsSame periodMethods of evaluationCancerBreast
2011
Using Nodal Ratios to Predict Risk of Regional Recurrences in Patients Treated with Breast Conservation Therapy with 4 or More Positive Lymph Nodes
Castrucci W, Lannin D, Haffty BG, Higgins SA, Moran MS. Using Nodal Ratios to Predict Risk of Regional Recurrences in Patients Treated with Breast Conservation Therapy with 4 or More Positive Lymph Nodes. International Scholarly Research Notices 2011, 2011: 874814. PMID: 22084784, PMCID: PMC3200302, DOI: 10.5402/2011/874814.Peer-Reviewed Original ResearchHigher nodal ratioBreast conservation therapyNodal ratioLymph nodesRegional recurrenceConservation therapyRegional failureN2/N3 patientsPositive axillary lymph nodesPositive lymph nodesAxillary lymph nodesGroup of patientsIntensive systemic therapyN3 statusDistant failureN3 patientsNodal recurrenceSystemic therapyDose escalationEntire cohortRegional nodesBreast cancerInclusion criteriaPrognostic variablesHigh risk
2009
Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100).
Albain K, Barlow W, Shak S, Hortobagyi G, Livingston R, Yeh I, Ravdin P, Bugarini R, Baehner F, Davidson N, Sledge G, Winer E, Hudis C, Ingle J, Perez E, Pritchard K, Shepherd L, Gralow J, Yoshizawa C, Allred D, Osborne C, Hayes D. Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100). Cancer Research 2009, 69: 112-112. DOI: 10.1158/0008-5472.sabcs-09-112.Peer-Reviewed Original ResearchBreast cancer-specific survivalDisease-free survivalER-positive breast cancerAnthracycline-based chemotherapyCancer-specific survivalBreast cancerRecurrence scoreRS categorySuperior breast cancer-specific survivalDFS analysisNew adjuvant treatment strategiesPositive axillary lymph nodesAdjuvant treatment strategiesAxillary lymph nodesHigh-risk patientsUse of chemotherapyLow recurrence scoreHigh recurrence scoreLow RS groupNational Cancer InstituteLack of improvementLog-rank p-valueCensoring deathsLast followChemotherapy benefit
2008
Paclitaxel-induced sickle cell crisis
Wilson NM, Espirito JL, Valero V, Pusztai L. Paclitaxel-induced sickle cell crisis. American Journal Of Health-System Pharmacy 2008, 65: 1333-1336. PMID: 18593679, DOI: 10.2146/ajhp070432.Peer-Reviewed Original ResearchConceptsSickle cell diseaseHemoglobin sickle cell diseaseSickle cell crisisMetastatic diseasePainful crisesCell crisisBreast cancerAxillary lymph node dissectionPostmenopausal African-American womenLiver function test valuesLow-dose oxycodoneLymph node dissectionAxillary lymph nodesShortness of breathHistory of cancerSickle cell traitAfrican American womenRib painWeekly paclitaxelChemotherapy regimenNode dissectionSegmental mastectomyBone scanLeft breastLymph nodesQS127. Response of Axillary Lymph Nodes to Neoadjuvant Chemotherapy Parallels Primary Tumor Response in Breast Cancer Patients
Pilavas J, Napper L, Clements K, Chagpar A. QS127. Response of Axillary Lymph Nodes to Neoadjuvant Chemotherapy Parallels Primary Tumor Response in Breast Cancer Patients. Journal Of Surgical Research 2008, 144: 318. DOI: 10.1016/j.jss.2007.12.367.Peer-Reviewed Original Research
2006
Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer
Abu-Khalaf MM, Juneja V, Chung GG, DiGiovanna MP, Sipples R, McGurk M, Zelterman D, Haffty B, Reiss M, Wackers FJ, Lee FA, Burtness BA. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast Cancer Research And Treatment 2006, 104: 341-349. PMID: 17051423, DOI: 10.1007/s10549-006-9413-7.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionEnd of chemotherapyEquilibrium radionuclide angiographyBreast cancerAdjuvant therapySequential doxorubicinCardiac functionIpsilateral axillary lymph nodesHigh-risk breast cancerRisk breast cancerClinical heart failureInitiation of chemotherapyAxillary lymph nodesVentricular ejection fractionEnd of therapyLong-term cardiotoxicityMedian absolute changeEligible patientsFilgrastim supportLate cardiotoxicityAxillary nodesAsymptomatic declineEjection fractionHeart failureLymph nodes
2005
Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer
Abu-Khalaf MM, Windsor S, Ebisu K, Salikooti S, Ananthanarayanan G, Chung GG, DiGiovanna MP, Haffty BG, Abrams M, Farber LR, Hsu AD, Reiss M, Zelterman D, Burtness BA. Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer. Oncology 2005, 69: 372-383. PMID: 16319508, DOI: 10.1159/000089991.Peer-Reviewed Original ResearchConceptsHigh-risk breast cancerBreast cancerAdjuvant therapyLymph nodesCommon grade 3 toxicitiesIpsilateral axillary lymph nodesGrade 3 toxicityGrade 3/4 neutropeniaPhase II studyAxillary lymph nodesPalmar-plantar erythrodysesthesiaDose-denseEligible patientsFeasible regimenFilgrastim supportNeutropenic feverDistant diseaseAxillary nodesDose intensityII studyBC surgerySequential doxorubicinAcute leukemiaMetastatic cancerMedian numberAmerican Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer. Journal Of Clinical Oncology 2005, 23: 7703-7720. PMID: 16157938, DOI: 10.1200/jco.2005.08.001.Peer-Reviewed Original ResearchConceptsAxillary lymph node dissectionEarly-stage breast cancerSentinel node biopsyCompletion axillary lymph node dissectionBreast cancerNode biopsyUse of SNBSentinel lymph node biopsyNegative axillary nodesLymph node dissectionAxillary lymph nodesLymph node biopsyStage breast cancerHealth Services CommitteeLong-term survivalAmerican SocietyUnknown clinical significanceIsolated cancer cellsAxillary metastasesNode dissectionSLN biopsyAxillary nodesSentinel lymphSLN evaluationLymph nodes
2003
Systemic Tropheryma whippleii infection associated with monoclonal B-cell proliferation: a Helicobacter pylori-type pathogenesis?
Wang S, Ernst LM, Smith BR, Tallini G, Howe JG, Crouch J, Cooper DL. Systemic Tropheryma whippleii infection associated with monoclonal B-cell proliferation: a Helicobacter pylori-type pathogenesis? Archives Of Pathology & Laboratory Medicine 2003, 127: 1619-22. PMID: 14632565, DOI: 10.5858/2003-127-1619-stwiaw.Peer-Reviewed Original ResearchConceptsMonoclonal B-cell proliferationLymph nodesB cell proliferationWhipple's diseasePeripheral bloodPolymerase chain reactionB cellsRight axillary lymph nodeAxillary lymph nodesMesenteric lymph nodesMonoclonal B-cell populationTime of presentationPatients' peripheral bloodPrevious biopsy specimensChain reactionB-cell lymphomaMonoclonal B cellsB cell populationsPeriodic acid-Schiff stainFlow cytometry studiesRoutine cytogenetic studiesEntire followMesenteric lymphBiopsy specimensImmunohistochemical stainsSequential High‐Dose Alkylating Therapy and Stem Cell Support for High‐Risk Stage III Breast Cancer
Bou‐Khalil J, Rose M, Psyrri A, D’Andrea E, Medoff E, Staugaard‐Hahn C, Holtkamp C, Gran S, Pezzimente J, Snyder E, Cooper D, Haffty B, Reiss M, Burtness B. Sequential High‐Dose Alkylating Therapy and Stem Cell Support for High‐Risk Stage III Breast Cancer. The Breast Journal 2003, 9: 472-477. PMID: 14616941, DOI: 10.1046/j.1524-4741.2003.09604.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsConnecticutCyclophosphamideFemaleGranulocyte Colony-Stimulating FactorHumansMedical RecordsMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPaclitaxelPalliative CareRetrospective StudiesStem Cell TransplantationSurvival AnalysisTreatment OutcomeConceptsStem cell rescueAdvanced breast cancerBreast cancerCell rescueLymph nodesHormone receptor-positive tumorsIpsilateral axillary lymph nodesStandard-dose adjuvant chemotherapyWhite blood cell toxicityStage III breast cancerAnthracycline-containing chemotherapyPositive lymph nodesTreatment-related complicationsAxillary lymph nodesHigh-dose chemotherapyStem cell supportReceptor-positive tumorsGranulocyte colony-stimulating factorMajority of cancersColony-stimulating factorAdjuvant chemotherapyNeutropenic feverNeoadjuvant chemotherapyStage IIIBMedian time
2001
Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer
Tafra L, Verbanac K, Lannin D. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. The American Journal Of Surgery 2001, 182: 312-315. PMID: 11720661, DOI: 10.1016/s0002-9610(01)00718-8.Peer-Reviewed Original ResearchConceptsPrior chemotherapySentinel lymphadenectomyAxillary lymph nodesBreast cancerSentinel nodesPC groupLymph nodesSuspicious axillary lymph nodesSentinel node identification rateOnly exclusion criterionPositive axillary nodesAxillary node dissectionMean tumor sizeStandard of careNon-PC groupPresence of diseaseIsosulfan blueNode dissectionPreoperative chemotherapyAxillary nodesMetastatic diseaseMost patientsPC patientsMulticenter trialTumor sizeRealistic Monte Carlo Simulation of Ga-67 SPECT Imaging
Moore S, El Fakhri G. Realistic Monte Carlo Simulation of Ga-67 SPECT Imaging. IEEE Transactions On Nuclear Science 2001, 48: 720. DOI: 10.1109/23.940153.Peer-Reviewed Original ResearchRealistic Monte Carlo simulationsNumerical torso phantomLead X-raysMonte Carlo programPhoton emission energyPoisson noise realizationsGa-67 SPECT imagingCollimator penetrationDetector resolutionEnergy windowRSD phantomPhoton propagationPhoton scatteringTorso phantomHeart/thorax phantomAttenuation mapEnergy distributionEmission energyImproved variance reductionSPECT imagesPhantomGa-67 studiesNoise realizationsScatteringAxillary lymph nodes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply